drugset / Trial / NCT06403488

Letrozole Dose Increments in PCOS Patients Resistant to Letrozole

NCT06403488

Phase 3 Completed 102 enrolled Beni-Suef University
RandomizedParallel-groupOpen-labelTreatment

Summary

Objectives: To study the effect of Letrozole dose increments on ovulation rate and endometrial thickness as a primary outcomes in patients with polycystic ovary syndrome who previously resistant to letrazole conventional dose, and chemical and clinical pregnancy considered as secondary outcomes.

Timeline

Start
2023-10-01
Primary completion
2024-01-30
Completion
2024-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 7.5 mg
Subject Letrozole Other / unclassified 10 mg